Loading
DNA alkylator payloads chemically damage DNA regardless of whether the cell is dividing, and are aimed at slow-growing and resistant tumours.
DNA alkylator payloads, chiefly the duocarmycins and seco-DUBA, chemically damage DNA whether or not the cell is dividing, and they are aimed at slow-growing and resistant tumours. In preclinical models duocarmycin-type alkylators act independently of the cell cycle and are not cross-resistant with tubulin or topoisomerase payloads, which is the attraction. Clinical translation has nonetheless been slow: trastuzumab duocarmazine reached phase 3 but was not approved. The class belongs to the Antibody-drug conjugate (ADC) technology and the Payload (ADC) term, and it is referenced by the specific payload record Duocarmycin (seco-DUBA) and by the pathway on base excision repair, PARP and alkylation damage, which describes how cells respond to this kind of lesion.
Showing the technology this term belongs to: Antibody-drug conjugate (ADC).